Collegium Pharmaceutical, Inc. (COLL) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Collegium (COLL) Q1 2026: Jornay PM Revenue Climbs 36%, ADHD Portfolio Set for Acceleration
May 07, 2026
-
Collegium Pharmaceutical (COLL) Q4 2025: Journée PM Revenue Surges 48%, Anchoring Portfolio Diversification
February 26, 2026
-
Collegium (COLL) Q3 2025: Journay PM Revenue Jumps 46% as ADHD Franchise Accelerates
November 06, 2025
-
Collegium (COLL) Q2 2025: Jornay PM Drives 23% Rx Growth, Powering Guidance Raise and Portfolio Durability
August 07, 2025
-
Collegium (COLL) Q1 2025: Jornay Scripts Up 24% as ADHD Expansion Outpaces Pain Portfolio
July 05, 2025